Epix falls after dropping PRX-00023

Epix fell $1.65 (54%) to $1.43 on Thursday after it discontinued development of PRX-00023. The decision came after data from a Phase IIb trial of the dual serotonin (5-HT1A) receptor agonist and sigma...